Compare Stocks: ATYR, MDWD, OTLK, and LUCD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.36 -3.6%	$0.49	$0.36 ▼ $1.12	$35.61M	0.53	742,724 shs	1.26 million shs
LUCD Lucid Diagnostics	$0.79 +0.7%	$0.94	$0.75 ▼ $1.63	$159.69M	1.1	887,482 shs	2.38 million shs
MDWD MediWound	$13.40 +0.4%	$13.73	$12.52 ▼ $20.03	$172.22M	0.14	120,052 shs	81,943 shs
OTLK Oncobiologics	$0.65 -4.2%	$0.92	$0.16 ▼ $2.54	$158.87M	0.74	6.19 million shs	5.60 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	-15.54%	-27.83%	-19.42%	-64.59%
LUCD Lucid Diagnostics	0.00%	+0.36%	-18.19%	-26.23%	-26.57%
MDWD MediWound	0.00%	+2.21%	+2.21%	-5.90%	-19.81%
OTLK Oncobiologics	0.00%	-1.12%	-3.50%	-58.70%	-36.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.36 -3.6%	$0.49	$0.36 ▼ $1.12	$35.61M	0.53	742,724 shs	1.26 million shs
LUCD Lucid Diagnostics	$0.79 +0.7%	$0.94	$0.75 ▼ $1.63	$159.69M	1.1	887,482 shs	2.38 million shs
MDWD MediWound	$13.40 +0.4%	$13.73	$12.52 ▼ $20.03	$172.22M	0.14	120,052 shs	81,943 shs
OTLK Oncobiologics	$0.65 -4.2%	$0.92	$0.16 ▼ $2.54	$158.87M	0.74	6.19 million shs	5.60 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	-15.54%	-27.83%	-19.42%	-64.59%
LUCD Lucid Diagnostics	0.00%	+0.36%	-18.19%	-26.23%	-26.57%
MDWD MediWound	0.00%	+2.21%	+2.21%	-5.90%	-19.81%
OTLK Oncobiologics	0.00%	-1.12%	-3.50%	-58.70%	-36.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.67	Moderate Buy	N/A	N/A
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	432.96% Upside
MDWD MediWound	2.40	Hold	$33.00	146.27% Upside
OTLK Oncobiologics	2.20	Hold	$5.20	696.81% Upside

Current Analyst Ratings Breakdown

Latest ATYR, MDWD, OTLK, and LUCD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	187.40	N/A	N/A	$0.69 per share	0.53
LUCD Lucid Diagnostics	$4.71M	33.90	N/A	N/A	($0.31) per share	-2.53
MDWD MediWound	$16.96M	10.15	N/A	N/A	$3.40 per share	3.94
OTLK Oncobiologics	$1.35M	117.69	N/A	N/A	($0.60) per share	-1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	N/A

Latest ATYR, MDWD, OTLK, and LUCD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.12
LUCD Lucid Diagnostics	N/A	1.33	1.31
MDWD MediWound	N/A	2.32	2.09
OTLK Oncobiologics	N/A	0.81	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
LUCD Lucid Diagnostics	74.01%
MDWD MediWound	46.83%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
LUCD Lucid Diagnostics	6.90%
MDWD MediWound	9.20%
OTLK Oncobiologics	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	58	98.09 million	92.45 million	Optionable
LUCD Lucid Diagnostics	82	203.24 million	189.22 million	No Data
MDWD MediWound	121	12.85 million	11.67 million	Optionable
OTLK Oncobiologics	17	243.45 million	239.07 million	Optionable

ATYR, MDWD, OTLK, and LUCD Headlines

Recent News About These Companies

Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Update

September 19 at 3:22 AM | americanbankingnews.com

FY2026 EPS Forecast for Oncobiologics Lifted by Analyst

September 19 at 1:13 AM | americanbankingnews.com

Oncobiologics (NASDAQ:OTLK) and Synlogic (NASDAQ:SYBX) Critical Comparison

September 18 at 4:58 AM | americanbankingnews.com

Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Up 65.4% in August

September 17 at 8:59 AM | marketbeat.com

Brokers Offer Predictions for Oncobiologics FY2026 Earnings

September 17 at 7:11 AM | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Price Target Raised to $10.50 at Ascendiant Capital Markets

September 11, 2026 | marketbeat.com

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026 | globenewswire.com

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

September 10, 2026 | globenewswire.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Hold" by Brokerages

September 9, 2026 | americanbankingnews.com

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Hold" from Analysts

September 9, 2026 | marketbeat.com

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

August 27, 2026 | globenewswire.com

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

August 27, 2026 | globenewswire.com

Analysts Issue Forecasts for Oncobiologics FY2026 Earnings

August 21, 2026 | marketbeat.com

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

August 17, 2026 | zacks.com

Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)

August 15, 2026 | defenseworld.netD

Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock

August 15, 2026 | insidertrades.com

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

August 14, 2026 | zacks.com

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

August 14, 2026 | globenewswire.com

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

August 14, 2026 | benzinga.com

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

August 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, MDWD, OTLK, and LUCD Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.36 -0.01 (-3.59%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.37 +0.01 (+3.03%)

As of 09/18/2026 07:30 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Lucid Diagnostics NASDAQ:LUCD

$0.79 +0.01 (+0.68%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.42%)

As of 09/18/2026 07:52 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

MediWound NASDAQ:MDWD

$13.40 +0.05 (+0.37%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.41 +0.01 (+0.07%)

As of 09/18/2026 04:10 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Oncobiologics NASDAQ:OTLK

$0.65 -0.03 (-4.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.68 +0.03 (+4.20%)

As of 09/18/2026 07:51 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, MDWD, OTLK, and LUCD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, MDWD, OTLK, and LUCD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, MDWD, OTLK, and LUCD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, MDWD, OTLK, and LUCD Company Descriptions

aTyr Pharma NASDAQ:ATYR

Lucid Diagnostics NASDAQ:LUCD

MediWound NASDAQ:MDWD

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, MDWD, OTLK, and LUCD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, MDWD, OTLK, and LUCD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, MDWD, OTLK, and LUCD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, MDWD, OTLK, and LUCD Company Descriptions

aTyr Pharma NASDAQ:ATYR

Lucid Diagnostics NASDAQ:LUCD

MediWound NASDAQ:MDWD

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools